Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566679 | 1.00 | NPC1 (0.44) | NPC1RAB9ACTRB1SLC15A1CYP1A2 | |
| SCHEMBL5566685 | 1.00 | NPC1 (0.44) | NPC1RAB9ACTRB1SLC15A1CYP1A2 | |
| SCHEMBL13537468 | 0.88 | NPC1 (0.41) | NPC1RAB9ACTRB1SLC15A1CYP1A2 | |
| SCHEMBL4728419 | 0.81 | NPC1 (0.50) | NPC1RAB9ACTRB1CYP1A2BACE1 | |
| SCHEMBL924912 | 0.81 | NPC1 (0.42) | NPC1RAB9ASLC15A1TAAR1BACE1 | |
| SCHEMBL6740451 | 0.81 | KLK5 (0.57) | — | |
| SCHEMBL6739450 | 0.81 | KLK5 (0.57) | — | |
| SCHEMBL6875883 | 0.81 | KLK5 (0.57) | — | |
| SCHEMBL7276408 | 0.81 | KLK5 (0.57) | — | |
| SCHEMBL4829636 | 0.80 | BACE1 (0.37) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | NPC1 1445/4885RAB9A 1606/4885CTRB1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.